401 Health-related quality of life following [18F]FDG-PET/CT 7 For the ThyPRO, scores range from 0 (best score) to 100 (worst score). *: P value indicates the between-group difference for that assessment, using an independent samples t-test and using the benign histopathology group as reference category (ref.). †: P value indicates whether the within-group difference between two assessments is statistically significant, using a paired samples t-test. §: Indicates clinically relevant difference using the MIC values established by Nordqvist et al. [599]. Table 4. Longitudinal within-group changes in ThyPRO scores Mean difference over time, within group Baseline v 3 months Baseline v 6 months Baseline v 12 months 3 v 12 months ThyPRO mean diff p† mean diff p† mean diff p† mean diff p† Goitre Symptoms Malignant 4.1 0.36 0.1 0.98 -5.7 0.09 -9.8 0.02§ Benign 5.6 0.02 -1.4 0.57 -6.8 0.001§ -12.4 <0.001§ Active surveillance -2.7 0.42 -3.2 0.18 -1.0 0.76 1.7 0.61 Hyperthyroid Symptoms Malignant 2.8 0.49 4.3 0.22 3.1 0.19 0.3 0.93 Benign 1.0 0.56 3.0 0.16 4.6 0.02 3.6 0.07 Active surveillance 1.3 0.62 -0.7 0.84 -0.6 0.79 -1.9 0.41 Hypothyroid Symptoms Malignant 1.1 0.83 3.5 0.37 1.6 0.68 0.5 0.92 Benign -2.6 0.29 1.9 0.48 1.4 0.62 4.0 0.14 Active surveillance 1.1 0.79 2.9 0.52 -1.5 0.64 -2.6 0.36 Eye Symptoms Malignant 5.6 0.16 4.7 0.20 0.8 0.76 -4.8 0.21 Benign 2.5 0.20 2.6 0.20 3.2 0.10 0.7 0.72 Active surveillance -0.8 0.80 -0.5 0.86 -1 0.69 -0.3 0.92 Tiredness Malignant 3.3 0.44 4.1 0.23 2.9 0.51 -0.5 0.91 Benign 6.7 0.01 1.9 0.46 1.6 0.55 -5.1 0.08 Active surveillance -1.2 0.74 -0.1 0.99 -2 0.44 -0.8 0.80 Cognitive Impairment Malignant 7.4 0.11§ 7.5 0.04§ 3.9 0.14 -3.4 0.43 Benign 4.8 0.05 5.6 0.03 6.6 0.007 1.8 0.45 Active surveillance -0.2 0.94 -0.9 0.76 0.3 0.91 0.5 0.87 Anxiety Malignant 2.1 0.60 -1.1 0.78 -7.2 0.03 -9.3 0.03 Benign 0.3 0.89 -2.6 0.34 -5.1 0.06 -5.4 0.06 Active surveillance -2.8 0.33 -2.2 0.60 -1.6 0.61 1.2 0.71 Depressivity Malignant 3.3 0.49 2.9 0.46 -1.8 0.53 -5.1 0.24 Benign 0.7 0.75 3.1 0.25 0.3 0.90 -0.4 0.87 Active surveillance -5.6 0.12 -1.7 0.67 -1.8 0.54 3.8 0.15 Emotional Susceptibility Malignant 4.3 0.28 2.8 0.40 -0.8 0.81 -5.1 0.20 Benign 2.7 0.23 2.9 0.26 1.8 0.49 -0.9 0.71 Active surveillance -1.7 0.57 -0.7 0.83 2.6 0.34 4.3 0.11 Social Impairment Malignant 4.9 0.23 6.3 0.12§ 0.8 0.80 -4.1 0.30 Benign 3.0 0.20 9.4 0.001§ 2.7 0.32 -0.3 0.89 Active surveillance -4.3 0.20 -2.4 0.53 -3.9 0.29 0.4 0.92 Impaired Daily Life Malignant 9.9 0.06§ 6.7 0.02 2.7 0.48 -7.2 0.21 Benign 12.1 <0.001§ 9.4 0.002§ 3.9 0.14 -8.1 0.01§ Active surveillance -2.2 0.52 -1 0.81 -4.3 0.22 -2.1 0.37 Impaired Sex Life Malignant 4.4 0.48 4.4 0.36 1.8 0.77 -2.6 0.71 Benign 7.5 0.05 3.4 0.38 3.5 0.39 -4.0 0.35 Active surveillance -6.8 0.26 -4.5 0.42 -7.0 0.19 -0.2 0.97 Cosmetic Complaints Malignant 8.1 0.08 4.9 0.16 3.0 0.33 -5.1 0.25 Benign 5.0 0.03 8.4 0.002§ 5.1 0.03 0.1 0.98 Active surveillance -6.0 0.07 -1.0 0.79 -3.2 0.35 2.8 0.36 Negative Influence on QoL Malignant 8.1 0.34 1.0 0.86 -5.5 0.39 -13.6 0.06§ Benign 4.3 0.42 -3.6 0.42 -7.2 0.14 -11.5 0.03§ Active surveillance -6.4 0.28 -6.4 0.34 -9.9 0.09§ -3.5 0.51 ThyPRO Composite QoL Malignant 5.2 0.17 4.0 0.12 -0.4 0.86 -5.6 0.12 Benign 4.5 0.01 3.8 0.06 0.9 0.63 -3.6 0.06 Active surveillance -2.4 0.27 -1.7 0.53 -1.4 0.48 1.1 0.60
RkJQdWJsaXNoZXIy MTk4NDMw